News Brief

The Juvenile Diabetes Research Foundation recently announced a partnership with and Palo Alto-based Bayhill Therapeutics Inc.  JDRF will provide funding in support of Bayhill’s ongoing human clinical trial of a DNA vaccine to reverse the immune response that causes Type 1 diabetes. Bayhil, a developer of therapies for autoimmune diseases will receive up to $3 million toward the clinical trial, depending on certain clinical milestones being reached by Fall 2009.